Exchange: NASDAQ·Updated 02:55 PM EDT
IMUX logo

IMUX Immunic Inc

$12.70
$0.06
(0.47%)
Today
Reported EarningsAug 11
Mkt Cap$174.1M
Vol200,229.00

About IMUX

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on multiple sclerosis, celiac disease and other neurologic and gastrointestinal disorders. The firm's products include IMU-838, IMU-856, and IMU-381. The company was founded in 2016 and is headquartered in New York, NY.
48

Neutral Sentiment

How do you feel about IMUX?

Advertisement|Remove ads.